Genetic Office Announces Dates for Approval Meetings in the Second Half of 2021


To all relevant units:
 
To further enhance the quality of administrative approval services for human genetic resources and to enable applicants to better track the progress of their applications, the scheduled dates for the Administrative Licensing Review Meetings of the China Office for the Administration of Human Genetic Resources in the second half of 2021 are hereby announced. Should special circumstances necessitate adjustments to the meeting schedule, advance notice will be provided.

 

 

Batch

Time

The 13th batch of 2021

July 5, 2021

The 14th batch of 2021

July 19, 2021

The 15th batch of 2021

August 2, 2021

The 16th batch of 2021

August 16, 2021

The 17th batch of 2021

August 30, 2021

The 18th batch of 2021

September 13, 2021

The 19th batch of 2021

September 27, 2021

The 20th batch of 2021

October 18, 2021

The 21st batch of 2021

November 1, 2021

Batch 22 of 2021

November 15, 2021

The 23rd batch of 2021

November 29, 2021

Batch 24 of 2021

December 13, 2021

Batch 25 of 2021

December 27, 2021

      

 Office of Human Genetic Resources Administration of China

 

July 1, 2021

 

Related News


(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.


(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.


Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.


A novel mechanism by which iron overload in the tumor microenvironment triggers ferroptosis in CD8⁺ T cells | Guangzhou National Laboratory publishes in Nature Communications, revealing a key pathway of immune evasion (IF: 18.2)

Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.


Hycells Recruitment | Never Stop Exploring, Never Stop Innovating

The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.


3.0 High-Efficiency Version of HiXpan® NK Serum-Free Culture Kit | Chapter 4: Comprehensive Overview of Customer-Specific Culture Data Across Multiple Scenarios

The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.